The pathology of and controversial aspects of ovarian borderline tumours

Current Opinion in Oncology

Volumn 22, Issue 5, 2010, Pages 462-472

  McCluggage, W Glenn ^a  

^a ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

Author keywords

mucinous borderline tumour; ovary; pathology; serous borderline tumour

Indexed keywords

ADENOCARCINOMA; BEHAVIOR; CANCER GRADING; CANCER INVASION; CANCER RISK; CANCER STAGING; CARCINOMA; CLINICAL ASSESSMENT; CLINICAL FEATURE; CYSTADENOMA; DIAGNOSTIC TEST; DISEASE COURSE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMPLANT; INVASIVE CARCINOMA; LYMPH NODE; LYMPH NODE METASTASIS; MUCINOUS CARCINOMA; NOMENCLATURE; ONCOGENE K RAS; OVARY TUMOR; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEROUS CARCINOMA; STROMA; TUMOR VOLUME;

CYSTADENOMA, MUCINOUS; CYSTADENOMA, SEROUS; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 77955428905     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32833b0dc1     Document Type: Review

References (59)

1. Taylor HC. Malignant and semimalignant tumors of the ovary. Surg Gynecol Obstet 1929; 46:208-230.
2. Tavassoli FA, Devilee P, editors. World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of the Breast and Female Genital Organs. Lyon, IARC Press, 2003.
3. Singer G, Shih IM, Truskinovsky A, et al. Mutational analysis of K-ras segregate ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma. Int J Gynecol Pathol 2003; 22:37-41.
4. Singer G, Stohr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low and high grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 2005; 29:218-224.
5. Shih IM, Kurman RJ. Ovarian tumorigenesis. A proposed model based on morphological and molecular genetic analysis. AmJ Pathol 2004; 164:1511-1518.
6. Russell HE, McCluggage WG. A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes. J Pathol 2004; 203:617-619.
7. Singer G, Kurman RJ, Chang HW, et al. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 2002; 160:1223-1228.
8. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007; 31:161-169.
9. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007; 211:26-35.
10. Herrington CS, McCluggage WG. The emerging role of the distal fallopian tube and p53 in pelvic serous carcinogenesis. J Pathol 2010; 220:5-6.
11. Silverberg SG. Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 2000; 19:7-15.
12. Wilkinson N, McCluggage WG. Datasets for the histopathological reporting of neoplasms of the ovaries and fallopian tubes and primary carcinomas of the peritoneum. Royal College of Pathologists 2008.
13. Dehari R, Kurman RJ, Logani S, et al. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis. Am J Surg Pathol 2007; 31:1007-1012.
14. Ho C-L, Kurman RJ, Dehari R, et al. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Can Res 2004; 64:6915-6918.
15. Sieben NLG, Macropoulos P, Roemen GMJM, et al. In ovarian neoplasms, BRAF, but not KRAS, mutation are restricted to low-grade serous tumours. J Pathol 2004; 202:336-340.
16. Kurman RJ, Seidman JD, Shih IM. Serous borderline tumours of the ovary. Histopathology 2005; 47:310-315.
17. Bell DA, LongacreTA, Prat J, et al. Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives. Hum Pathol 2004; 35:934-948.
18. Seidman JD, Kurman RJ. Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced-stage cases. Am J Surg Pathol 1996; 20:1331-1345.
19. Burks RT, Sherman ME, Kurman RJ. Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors. Am J Surg Pathol 1996; 20:1319-1330.
20. Eichhorn JH, Bell DA, Young RH, et al. Ovarian serous borderline tumors with micropapillary and cribriform pattern: a study of 40 cases and comparison with 44 cases without these patterns. Am J Surg Pathol 1999; 23:397-409.
21. Prat J, De Nictolis M. Serous borderline tumors of the ovary: a long term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion. Am J Surg Pathol 2002; 26:1111-1128.
22. Bell DA, Scully RE. Ovarian serous borderline tumors with stromal micro-invasion: a report of 21 cases. Hum Pathol 1990; 21:397-403.
23. Kennedy AW, Hart WR. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma. Cancer 1996; 78:278-286.
24. Kurman RJ, Seidman JD. Ovarian serous borderline tumors: the citadel defended. Hum Pathol 2000; 31:1439-1442.
25. Silva EG, Kurman RJ, Russell P, Scully RE. Symposium: ovarian tumors of borderline malignancy. Int J Gynecol Pathol 1996; 15:281-302.
26. Bell KA, Smith SehdevAE, Kurman RJ. Refined diagnostic criteria for implants associated with ovarian atypical proliferative serous tumors (borderline) and micropapillary serous carcinomas. Am J Surg Pathol 2001; 25:419-432.
27. Lu KH, Bell DA, Welch WR, et al. Evidence of the multifocal origin of bilateral and advanced human serous borderline ovarian tumors. Cancer Res 1998; 58:2328-2330.
28. Gu J, Roth LM, Younger C, et al. Molecular evidence for the independent origin of extra-ovarian papillary serous tumors of low malignant potential. J Natl Cancer Inst 2001; 93:1147-1152.
29. McKenney JK, Balzer BL, Longacre TA. Lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors): pathology, prognosis, and proposed classification. Am J Surg Pathol 2006; 30:614-624.
30. Djordjevic B, Malpica A. Lymph node involvement in ovarian serous tumors of low malignant potential: a clinicopathologic study of thirty-six cases. Am J Surg Pathol 2010; 34:1-9.
31. Fadare O. Recent developments on the significance and pathogenesis of lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors). Int J Gynecol Cancer 2009; 19:103-108.
32. Verbruggen MB, Verheijen RH, van de Goot FR, et al. Serous borderline tumor of the ovary presenting with cervical lymph node involvement: a report of 3 cases. Am J Surg Pathol 2006; 30:739-743.
33. Fadare O, Orejudos MP, Jain R, et al. A comparative analysis of lymphatic vessel density in ovarian serous tumors of low malignant potential (borderline tumors) with and without lymph node involvement. Int J Gynecol Pathol 2008; 27:483-490.
34. Silverberg SG, Bell DA, Kurman RJ, et al. Borderline ovarian tumors: key points and workshop summary. Hum Pathol 2004; 35:910-917.
35. Longacre TA, McKenney JK, Tazelaar HD, et al. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up. Am J Surg Pathol 2005; 29:707-723.
36. Seidman JD, Kurman RJ. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol 2000; 31:539-557.
37. Ronnett BM, Kajdacsy-Balla A, Gilks CB, et al. Mucinous borderline ovarian tumors: points of general agreement and persistent controversies regarding nomenclature, diagnostic criteria, and behaviour. Hum Pathol 2004; 35:949-960.
38. Hart WR. Mucinous tumors of the ovary: a review. Int J Gynecol Pathol 2005; 24:4-25.
39. McCluggage WG. My approach to and thoughts on typing of ovarian carcinomas. J Clin Pathol 2008; 61:152-163.
40. Lerwill MF, Young RH. Mucinous tumours of the ovary. Diagn Histopathol 2008; 14:366-387.
41. Cantrecasas M, Villaneuva A, Matias-Guiu X, Prat J. K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases. Cancer 1997; 70:1581-1586.
42. Tenti P, Aguzzi A, Riva C, et al. Ovarian mucinous tumors frequently express markers of gastric, intestinal and pancreaticobiliary epithelial cells. Cancer 1992; 69:2131-2142.
43. Prat J, Scully RE. Ovarian mucinous tumors with sarcoma-like mural nodules: a report of seven cases. Cancer 1979; 44:1322-1344.
44. Provenza C, Young RH, Prat J. Anaplastic carcinoma in mucinous ovarian tumors. A clinicopathologic study of 34 cases emphasizing the crucial impact of stage on prognosis, their histologic spectrum, and overlap with sarcomalike mural nodules. Am J Surg Pathol 2008; 32:383-389.
45. McCluggage WG, Wilkinson N. Metastatic neoplasms involving the ovary: a review with an emphasis on morphological and immunohistochemical features. Histopathology 2005; 47:231-247.
46. Lee KR, Young RH. The distinction between primary and secondary mucinous carcinomas of the ovary: gross and histologic findings in 50 cases. Am J Surg Pathol 2003; 27:281-292.
47. Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinomas in the ovary: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol 2003; 27:985-993.
48. Ronnett BM, Kurman RJ, Zahn CM, et al. Pseudomyxoma peritonei in women: a clinicopathologic analysis of 30 cases with emphasis on site of origin, prognosis, and relationship to ovarian mucinous tumors of low malignant potential. Hum Pathol 1995; 26:509-524.
49. Ronnett BM, Zahn CM, Kurman RJ, et al. Disseminated peritoneal adenomu-cinosis and peritoneal mucinous carcinomatosis: a clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis and relationship to "pseudomyxoma peritonei". Am J Surg Pathol 1995; 19:1390-1408.
50. Ronnett BM, Shmookler BM, Diener-West M, et al. Immunohistochemical evidence supporting the appendiceal origin of pseudomyxoma peritonei in women. Int J Gynecol Pathol 1997; 16:1-9.
51. Shappell HW, Riopel MA, Smith Sehdev AE, et al. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas. Am J Surg Pathol 2002; 26:1529-1541.
52. Lee KR, Nucci MR. Ovarian mucinous and mixed epithelial carcinomas of mullerian (endocervical-like) type: a clinicopathologic analysis of four cases of an uncommon variant associated with endometriosis. Int J Gynecol Pathol 2003; 22:42-51.
53. Rodriguez IM, Irving JA, Prat J. Endocervical-like mucinous borderline tumors of the ovary: a clinicopathologic analysis of 31 cases. Am J Surg Pathol 2004; 28:1311-1318.
54. Kim KR, Choi J, Hwang JE, et al. Endocervical-like (Mullerian) mucinous borderline tumours of the ovary frequently associated with KRAS mutation. Histopathology (in press).
55. Vang R, Gown AM, Barry TS, et al. Ovarian atypical proliferative (borderline) mucinous tumors: gastrointestinal and seromucinous (endocervical-like) types are immunophenotypically distinctive. Int J Gynecol Pathol 2006; 25:83-89.
56. Vang R, Gown AM, Barry TS, et al. Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic muci-nous tumors in the ovary: an analysis of 124 cases. Mod Pathol 2006; 19:97-105.
57. Yasunaga M, Ohishi Y, Oda Y, et al. Immunohistochemical characterization of mullerian mucinous borderline tumors: possible histogenetic link with serous borderline tumors and low-grade endometrioid tumors. Hum Pathol 2009; 40:965-974.
58. Kelly P, Archbold P, Price JH, et al. Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype. J Clin Pathol 2010; 63:169-173.
59. Chiesa AG, Deavers MT, Veras E, et al. Ovarian intestinal type mucinous borderline tumors: are we ready for a nomenculature change? Int J Gynecol Pathol 2010; 29:108-112